| Literature DB >> 27842070 |
Sebastian Doll1, Bettina Proneth1, Yulia Y Tyurina2, Elena Panzilius3, Sho Kobayashi1, Irina Ingold1, Martin Irmler4, Johannes Beckers4, Michaela Aichler5, Axel Walch5, Holger Prokisch6,7, Dietrich Trümbach1, Gaowei Mao2, Feng Qu2, Hulya Bayir2, Joachim Füllekrug8, Christina H Scheel3, Wolfgang Wurst1, Joel A Schick1, Valerian E Kagan2, José Pedro Friedmann Angeli1, Marcus Conrad1.
Abstract
Ferroptosis is a form of regulated necrotic cell death controlled by glutathione peroxidase 4 (GPX4). At present, mechanisms that could predict sensitivity and/or resistance and that may be exploited to modulate ferroptosis are needed. We applied two independent approaches-a genome-wide CRISPR-based genetic screen and microarray analysis of ferroptosis-resistant cell lines-to uncover acyl-CoA synthetase long-chain family member 4 (ACSL4) as an essential component for ferroptosis execution. Specifically, Gpx4-Acsl4 double-knockout cells showed marked resistance to ferroptosis. Mechanistically, ACSL4 enriched cellular membranes with long polyunsaturated ω6 fatty acids. Moreover, ACSL4 was preferentially expressed in a panel of basal-like breast cancer cell lines and predicted their sensitivity to ferroptosis. Pharmacological targeting of ACSL4 with thiazolidinediones, a class of antidiabetic compound, ameliorated tissue demise in a mouse model of ferroptosis, suggesting that ACSL4 inhibition is a viable therapeutic approach to preventing ferroptosis-related diseases.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27842070 PMCID: PMC5610546 DOI: 10.1038/nchembio.2239
Source DB: PubMed Journal: Nat Chem Biol ISSN: 1552-4450 Impact factor: 15.040